Опубликовать статью

Информационное партнерство

Инфоресурсы

Контакты

«

Vol. 12, Art. 97 (pp. 1197-1206)    |    2011       

»

The effect of haemocomponent therapy on immune status of patients with blood disorders

T.V. Glazanova, O.E. Rozanova, I.E. Pavlova, J.V. Chubukina, E.R. Shilova, V.E. Soldatenkov, L.N. Bubnova

Russian Research Institute of Hematology and Transfusiology, Russian Federal Medico-biological Agency,

Brief summary

Using multi-colour flow cytometry we have studied the changes of parameters of cell immunity during the course of red blood cell transfusions in patients with aplastic anaemia (n=54), of whom 61,1% have not received any red blood cell transfusions, 18,5% have received only leukodepleted red blood cells and 20,4% - washed, unfreezed red blood cells and erythrocyte mass. Also we have examined patients with haemophilia A (n=102), of whom 38,2% were red blood cell recipients. There have not been revealed any significant differences between examined groups in the amount of total T-cell population (CD3+) and its main immunoregulatory subsets (СD3+/CD4+ - T-helpers and CD3+/CD8+ - T-cytotoxic cells) and B-cells (CD19+). Nevertheless, we have revealed the mediate immunosuppressive effect of haemotransfusion therapy manifesting by changes of amount of minor lymphoid subsets: increase of percent of CD8+/CD3- cells and decrease of activated CD3+/DR+ and NKT (CD3+/CD16/56+ lymphocytes). The obtained data are the evidence that patients with history of multiple haemocomponent transfusions should be referred as a group with increased risk of secondary immune deficiency and infectious complications. This should be considered during prescribing of immunosupresive therapy to transfusion-dependent patients and while choosing the tactics of haemocomponent transfusions.


Key words

cell immunity, red blood cells, transfusions, haemocomponents, aplastic anaemia, haemophilia.

Reference list

1. J. Gorham. Transfusion tickles T cells through cross-priming // Blood. – 2006. – Vol. 107, N 1. – R. 6-7.


2. J.Waters. Trauma surgery and transfusion options // International Trauma Care. – 2008. – Vol. 18, N 1 – P. 66-69.


3. M. Raghavan, P. Marik, Anemia, Allogenic Blood Transfusion, Immunomodulation in the Critically Ill. // Chest. – 2005. - Vol.127. – P. 295-307.


4. Y. Min, Chen Gang, Fang Ling-ling, et al. Immunologic changes to autologous transfusion after operational trauma in malignant tumor patients. Neopterin and Interleukin-2 //Journal of Zhejiang University Science. – 2005. – Vol. 6B, N 1. – P.49-52.


5. O. Mathiesen, L.Lund, U.Brodthagen, P.Gandrup Leukocyte filtration does not affect lymphocyte subpopulations and NK cell function in recipients of blood transfusion // Vox Sang. – 1998. – Vol.74, N 1. – P.15-20.


6. J. Zimring, Gregory A. Hair, Seema S. Deshpande, and John T. Horan Immunization to minor histocompatibility antigens on transfused RBCs through crosspriming into recipient MHC class I pathways // Blood. – 2005. – Vol. 105, N 10. – P. 4106-4114.


7. R. Brutkiewicz, S. Venkataraman. Natural killer (NKT) cells and their role in antitumor immunity //Clin.Rev.in Oncol./Hematol. – 2002. – Vol. 41. – P.287-298.


8. S. Yang, J. Lee. Role of NKT cells in allogenic islet graft survival // Clin. immunol. – 2007. – Vol. 124. – P. 258-266.


9. Jakóbisiak M, Lasek W, Gołab J. Natural mechanisms protecting against cancer // Immunol.Lett. – 2003. – Vol. 15, N 9. – P. 103-122.


10. M. Nikolova, J.-D. Lelievre, M. Carriere, A. Bensussan, Y. Lévy. Treg modulate CD8 subsets through pd-1/pdl1 pathway // Blood. – 2009. – Vol. 113, N 19. – P. 4556-4565.


11. M. Terabe, J. Berzofsky. NKT cells in immunomodulation of tumor immunity: a new immunoregulatory axis. // Trends in Immunol. – 2007. – Vol. 28, N 11. – P. 491-496.